Literature DB >> 12671506

Treatment of osseous metastases in patients with renal cell carcinoma.

Sung Taek Jung1, Michelle A Ghert, John M Harrelson, Sean P Scully.   

Abstract

The records of 99 patients treated at one institution for osseous metastases secondary to renal cell carcinoma were reviewed. Patients were followed up for at least 24 months or until death. Survival was analyzed with respect to age, gender, disease-free interval, location of osseous metastases, number of osseous metastatic sites, resection of osseous metastases, and primary tumor resection. The mean age of the 72 men and 27 women was 60 years (range, 34-82 years) and the mean followup was 20 months (range, 2-81 months). Twenty-six patients (26%) had a solitary osseous metastasis, 47 patients (48%) had multiple osseous metastases, and 26 patients (26%) had additional visceral involvement such as the lung and brain at the time of diagnosis. In 49 patients (49%), the renal cell carcinoma was diagnosed concurrently with detection of the osseous metastasis. The presence of one osseous renal carcinoma metastasis, wide resection of the lesion, and a history of nephrectomy were identified as independent predictors of survival in patients with renal cell carcinoma. The eight patients who had wide resection of a solitary osseous metastasis in combination with a nephrectomy had a disease-specific survival rate of 100% (mean followup, 69 months; range, 24-76 months). Patients who present with these characteristics are candidates for aggressive surgical treatment with curative intent.

Entities:  

Mesh:

Year:  2003        PMID: 12671506     DOI: 10.1097/01.blo.0000059580.08469.3e

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  29 in total

1.  Digital metastasis presenting as infection.

Authors:  Vasileios Kontogeorgakos; Anastasios Korompilias; Miltiadis Georgousis; Dionysios Papachristou
Journal:  J Hand Microsurg       Date:  2010-12-31

2.  Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma.

Authors:  George E Manoukian; Nizar M Tannir; Eric Jonasch; Wei Qiao; Tamara M Haygood; Shi-Ming Tu
Journal:  Clin Genitourin Cancer       Date:  2011-10-01       Impact factor: 2.872

3.  Managing acrometastases treatment strategy with a case illustration.

Authors:  V Spiteri; A Bibra; N Ashwood; J Cobb
Journal:  Ann R Coll Surg Engl       Date:  2008-10       Impact factor: 1.891

4.  Metastasectomy and Targeted Therapy for Patients With Spinal Metastases of Renal Cell Carcinoma.

Authors:  Dmitrii Ptashnikov; Nikita Zaborovskii; Stanislav Kostrickii; Dmitrii Mikaylov; Sergei Masevnin; Oleg Smekalenkov; Irakli Kuparadze
Journal:  Int J Spine Surg       Date:  2020-12-29

Review 5.  Acrometastases.

Authors:  Andreas F Mavrogenis; George Mimidis; Zinon T Kokkalis; Eirini-Sofia Karampi; Irene Karampela; Panayiotis J Papagelopoulos; Apostolos Armaganidis
Journal:  Eur J Orthop Surg Traumatol       Date:  2013-09-08

6.  Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus.

Authors:  Ricardo A Rendon; Anil Kapoor; Rodney Breau; Michael Leveridge; Andrew Feifer; Peter C Black; Alan So
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

Review 7.  New challenges in kidney cancer management: integration of surgery and novel therapies.

Authors:  Javier Puente Vázquez; T Alonso Gordoa; J Moreno; L Poma; E Diaz Rubio; A Gomez; J Blazquez; J L Gonzalez Larriba
Journal:  Curr Treat Options Oncol       Date:  2015-03

8.  Bone metastases of the hand.

Authors:  G Morris; S Evans; J Stevenson; A Kotecha; M Parry; L Jeys; R Grimer
Journal:  Ann R Coll Surg Engl       Date:  2017-09       Impact factor: 1.891

9.  Trochanter/calcar preserving reconstruction in tumors involving the femoral head and neck.

Authors:  Hwan Seong Cho; Young-Kyun Lee; Yong-Chan Ha; Kyung-Hoi Koo
Journal:  World J Orthop       Date:  2016-07-18

10.  Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma.

Authors:  Yosuke Yasuda; Yasuhisa Fujii; Takeshi Yuasa; Shinichi Kitsukawa; Shinji Urakami; Shinya Yamamoto; Junji Yonese; Shunji Takahashi; Iwao Fukui
Journal:  Int J Clin Oncol       Date:  2012-09-11       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.